NCT06575400View on ClinicalTrials.gov

A Study to Test How Well Different Doses of BI 3804379 Are Tolerated by Healthy People

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

September 12, 2024

Primary Completion Date

March 6, 2026

Study Completion Date

March 6, 2026

Conditions
Healthy
Interventions
DRUG

BI 3804379

BI 3804379

DRUG

Placebo matching BI 3804379

Placebo matching BI 3804379

Trial Locations (1)

2650

SGS Life Science Services - Clinical Research, Edegem

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY